We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WOW:ASXWoolworths Group Ltd Analysis

Data as of 2026-06-24 - not real-time

A$39.37

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Woolworths is trading at the top of its 52‑week range with price firmly above the 20‑day, 50‑day and 200‑day simple moving averages, confirming a strong bullish bias on the chart. The RSI sits deep in overbought territory, suggesting short‑term momentum may be exhausted. Meanwhile the MACD line sits above its signal line and the histogram remains positive, reinforcing the current uptrend. Volume has been trending higher, adding conviction to the price advance. However, the company’s valuation metrics are extreme – the price‑to‑earnings multiple is sky‑high and the discounted cash‑flow estimate is less than half of the market price, indicating a sizable overvaluation. The dividend payout ratio exceeds earnings, raising concerns about the sustainability of the 2%‑plus yield.
Sector‑wise, Woolworths benefits from the defensive nature of grocery retail, and its beta is exceptionally low, implying limited market‑wide volatility. Nonetheless, the elevated 30‑day volatility, high valuation, and aggressive dividend policy combine to create material downside risk. The fear‑and‑greed index is in the “extreme greed” zone, hinting that market sentiment may be overly optimistic. Investors should weigh the strong technical momentum against the fundamental overvaluation and dividend sustainability issues before deciding on exposure.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near 52‑week high
  • bullish MACD confirmation
  • RSI in overbought zone

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • persistent high valuation multiples
  • dividend payout exceeding earnings
  • stable cash flow generation

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • DCF fair value far below market price
  • high PE relative to peers
  • limited growth outlook in a mature sector

Key Metrics & Analysis

Financial Health

Revenue Growth3.40%
Profit Margin0.85%
P/E Ratio80.3
ROE11.88%
ROA3.64%
Debt/Equity361.53
P/B Ratio10.4
Op. Cash FlowA$4.9B
Free Cash FlowA$2.3B

Technical Analysis

TrendBullish
RSI76.2
SupportA$34.23
ResistanceA$39.38
MA 20A$36.91
MA 50A$35.87
MA 200A$31.83
MACDBullish
VolumeIncreasing
Fear & Greed Index87.09

Valuation

Fair ValueA$15.19
Target PriceA$34.88
Upside/Downside-11.41%
GradeOvervalued
TypeValue
Dividend Yield2.32%

Risk Assessment

Beta0.09
Volatility18.82%
Sector RiskLow
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.